The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Local versus central laboratory discrepancies in the determination of triple-negative breast cancer (TNBC) status in a large phase III (CIBOMA/2004-01/GEICAM/2003-11) trial assessing adjuvant capecitabine (C) maintenance therapy after standard chemotherapy (CT) in early breast cancer (EBC) patients (pts).
M. Ruiz-Borrego
Other Remuneration - Roche
C. H. Barrios
No relevant relationships to disclose
A. Lluch
Honoraria - Roche
Other Remuneration - Roche
J. Bines
No relevant relationships to disclose
J. G. M. Segalla
No relevant relationships to disclose
A. Ruiz
Honoraria - Roche
L. Torrecillas
No relevant relationships to disclose
A. Llombart-Cussac
Honoraria - Roche
R. Torres
No relevant relationships to disclose
J. Á. Garcia Saenz
No relevant relationships to disclose
J. A. Lopez Garcia-Asenjo
No relevant relationships to disclose
H. L. Gomez
No relevant relationships to disclose
J. R. De la Haba
Consultant or Advisory Role - Roche
Honoraria - Roche
S. Reyes
No relevant relationships to disclose
E. Martinez
No relevant relationships to disclose
J. M. Baena
No relevant relationships to disclose
L. Perez-Michell
No relevant relationships to disclose
A. Rodriguez-Lescure
Research Funding - Roche
A. Anton
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Other Remuneration - Roche
M. Martin
Other Remuneration - Roche